[{"address1": "245 First Street, Riverview II", "address2": "18th Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 327 8778", "fax": "617 890 6595", "website": "https://www.cyclerion.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Dr. Regina  Graul Ph.D.", "title": "President", "fiscalYear": 2023, "totalPay": 372000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rhonda M. Chicko", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Todd  Milne Ph.D.", "title": "Senior Vice President of External Innovation", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Rennekamp", "title": "Associate Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.82, "open": 3.1499, "dayLow": 2.9552, "dayHigh": 3.1499, "regularMarketPreviousClose": 2.82, "regularMarketOpen": 3.1499, "regularMarketDayLow": 2.9552, "regularMarketDayHigh": 3.1499, "beta": 1.91, "forwardPE": -2.3282444, "volume": 813, "regularMarketVolume": 813, "averageVolume": 6656, "averageVolume10days": 2780, "averageDailyVolume10Day": 2780, "marketCap": 7673403, "fiftyTwoWeekLow": 1.75, "fiftyTwoWeekHigh": 5.25, "fiftyDayAverage": 2.91876, "twoHundredDayAverage": 2.986155, "currency": "USD", "enterpriseValue": 2932199, "floatShares": 1230162, "sharesOutstanding": 2515870, "sharesShort": 13507, "sharesShortPriorMonth": 17304, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0054, "heldPercentInsiders": 0.21903, "heldPercentInstitutions": 0.4063, "shortRatio": 2.11, "shortPercentOfFloat": 0.0081, "bookValue": 3.491, "priceToBook": 0.87367517, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -10467000, "trailingEps": -4.29, "forwardEps": -1.31, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CYCN", "underlyingSymbol": "CYCN", "shortName": "Cyclerion Therapeutics, Inc.", "longName": "Cyclerion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1552915800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dd748c39-0459-359f-9a4f-d9343a16eaf1", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.05, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 4588000, "totalCashPerShare": 1.824, "quickRatio": 3.579, "currentRatio": 3.678, "returnOnAssets": -0.46554002, "returnOnEquity": -1.50248, "freeCashflow": -6386125, "operatingCashflow": -11453000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]